Compare Mesoblast Limited (MESO) vs Palantir Technologies Inc (PLTR) Price & Performance

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Palantir (PLTR) trades at $135.63, up 2.46% today, showing strong momentum despite being 35% below its 52-week high. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company demonstrates exceptional growth with 2025 revenue of $4.48 billion and net income of $1.63 billion, though valuation metrics remain elevated with a P/E of 148.74 and P/S of 65.12. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.33 surpassing the $0.2774 forecast.

Palantir's AI software leadership and accelerating revenue growth present compelling long-term potential, but the premium valuation creates significant risk if growth moderates. Analyst consensus leans bullish with a $185.75 price target, though the stock faces headwinds from competitive pressures and market rotation out of high-multiple software names. The company's strong government contracts and commercial expansion provide stability, but investors should weigh rich multiples against execution risks.